ProMIS Neurosciences is trading 5.7% down at $9.01, with no company-specific announcement identified to explain the decline. - On October 13, 2026, XBI was down 2.01% in regular trading, while the broader market was only slightly lower. - The company’s latest listed release was the October 6 appointment of a chief commercial officer. - Biotech-sector pressure may provide context, but does not establish a direct cause for the stock’s decline.